No Picture
News

BioAtla Subsidiary, Himalaya Therapeutics, Will Develop And Commercialize CAB Products In Greater China Market

First Conditionally Active Biologics licensing participation in Greater China territory

SAN DIEGO, April 16, 2019 /PRNewswire/ — BioAtla ®, LLC, a global clinical-stage biotechnology company focused on the development of Conditionally Active Biolog… […]

No Picture
News

Cidara Therapeutics Selects First Clinical Development Candidate from its Cloudbreak Influenza (Antiviral) Program

SAN DIEGO–(BUSINESS WIRE)–Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company has selected the antiviral conjugate (AVC) CB-012 as its first cl… […]

No Picture
News

Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the Company has initiated ILLUMINATE-B, a global Phase 3 pediatric study of lumasiran, an investigational, subcu… […]

No Picture
News

Allele Biotechnology and SCM Lifescience Sign a Joint Research and Development Agreement to Develop iPSC-based Diabetes Treatment

SAN DIEGO–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24Cell&src=ctag" target="_blank"gt;$Celllt;/agt; lt;a href="https://twitter.com/hashtag/Allele_Biotech?src=hash" target="_blank"gt;#Allele_… […]